Publication of SARA-INT Phase II results for BIO101 Confirmation of Phase 3 readiness Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – March 17, 2025) – Biophytis SA (FP: ALBPS) (“Biophytis” or the “company”), a clinical-stage biotechnology company specialized in developing therapies for age-related diseases, is excited to announce a world premiere: …
Read More »Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – February 25, 2025) – Biophytis SA (FP: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking …
Read More »Biophytis Unveils Its Outlook Strategies for 2025
Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – February 11, 2025) – Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in …
Read More »Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
Paris, France and Cambridge, Massachusetts–(Newsfile Corp. – January 27, 2025) – Biophytis SA (FP: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris. …
Read More »